Analyst Jason McCarthy of Maxim Group maintained a Buy rating on ProMIS Neurosciences, with a price target of $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight ProMIS Neurosciences’ promising advancements and financial positioning. The company has made significant progress in its Phase 1b study for PMN310, an antibody targeting amyloid oligomers, which is a potential safer alternative to traditional plaque-targeting methods. With over half of the planned patient enrollment completed and no adverse events reported, the interim results are encouraging, and the study is expected to yield further data by the end of 2026.
Additionally, ProMIS has bolstered its financial standing through recent fundraising activities, securing substantial capital that extends its operational runway into 2026. This financial stability, combined with the Fast Track Designation for PMN310 in early Alzheimer’s treatment, positions the company well for future growth and development. These elements collectively underpin McCarthy’s optimistic outlook and Buy rating for ProMIS Neurosciences.
According to TipRanks, McCarthy is an analyst with an average return of -19.1% and a 29.92% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and OS Therapies Incorporated.